Affiliations: Institute for the Application of Nuclear Energy
– INEP, Department for Endocrinology and Immunoradiology, University of
Belgrade, Belgrade, Serbia | Clinical Center of Serbia, Department of Endocrine and
Cardiovascular Pathology, Belgrade, Serbia
Note: [] Corresponding author: Svetlana Savin, Institute for the
Application of Nuclear Energy – INEP, Department for Endocrinology and
Immunoradiology, University of Belgrade, Banatska 31b, P.O.Box 46, 11080 Zemun
– Belgrade, Serbia. Tel.: +381 11 2618 666; Fax: +381 11 2618 724;
E-mail: [email protected]
Abstract: We evaluated caveolin-1 expression in the human thyroid neoplasia
spectrum with the aim of examining differences in expression as detected by two
anti-caveolin-1 antibodies, and secondly, to investigate the association of
caveolin-1 expression levels with aggressive papillary thyroid carcinoma (PTC).
Immunohistochemical staining using sc894 or AV09019 antibodies revealed that
caveolin-1 was generally overexpressed in the PTC group as a whole (classical
and follicular variant) when compared to peritumoral tissue (PT), while it was
not detected in about half of follicular thyroid carcinoma (FTC) and majority
of follicular adenomas (FTA). Caveolin-1 expression decreased in the following
order: clPTC, fvPTC, FTC, PT and FTA. The diagnostic accuracy of AV09019 was
better than that of sc894 for discriminating: FTA from FTC, FTA or FTC from the
follicular variant of PTC, total PTC from nonmalignant tissue, and malignant
tumors from nonmalignant tissue. Spearman's analysis revealed positive
correlations of caveolin-1 expression and extrathyroidal invasion (p< 0.05)
in PTC for both antibodies. Additionally, AV09019 antibody correlated
caveolin-1 upregulation with pathological T status. To conclude, as an immunohistochemical marker AV09019 antibody
performed better than sc894 in distinguishing certain histotypes of thyroid
tumors. In addition, increased expression of caveolin-1 may be considered as an
indicator of papillary carcinoma progression.
